10x Genomics, Inc. (TXG) - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024. 10x Genomics is a life sciences technology company providing integrated solutions (instruments, consumables, and software) for single-cell and spatial biology analysis. The company operates primarily through its Chromium (single-cell) and Spatial (Visium and Xenium) portfolios. As of December 31, 2024, the company had sold a cumulative total of 7,039 instruments globally.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $610.8 million | $618.7 million | -1.3% |
| Gross Profit | $414.5 million | $409.3 million | +1.3% |
| Gross Margin | 68.0% | 66.0% | +200 bps |
| Net Loss | $(182.6) million | $(255.1) million | -28.4% (Improvement) |
| Operating Cash Flow | $6.7 million | $(15.2) million | Positive vs. Negative |
| Cash & Marketable Securities | $393.4 million | $388.7 million | N/A |
| Accumulated Deficit | $(1.47) billion | $(1.28) billion | N/A |
Note: The company reported a net loss per share of $1.52 for 2024 compared to $2.18 for 2023.
Material Changes vs. Prior Period
- Revenue Mix Shift: While total revenue declined slightly, the composition shifted significantly. Instrument revenue dropped 25% to $92.7 million (down $30.8 million), driven by lower volumes of Chromium and Spatial instruments. Conversely, Consumables revenue increased 3% to $493.4 million, driven by a 104% surge in Spatial consumables sales, partially offset by an 11% decline in Chromium consumables due to price decreases and product mix changes.
- Service Growth: Service revenue grew 57% to $24.6 million, reflecting increased uptake of extended warranty plans.
- Expense Management: Total operating expenses decreased 10% to $609.0 million. This was primarily due to the absence of a $61.0 million in-process research and development (IPR&D) charge recorded in 2023 related to the Centrillion Technologies acquisition. Research and Development (R&D) expenses decreased 2% year-over-year, and Selling, General, and Administrative (SG&A) expenses remained relatively flat.
- Inventory Charges: The company recorded $11.3 million in excess and obsolete inventory charges in 2024, compared to $7.8 million in 2023.
Guidance, Outlook, and Risks
- Pricing Strategy: Management expects to lower prices for certain products in 2025 to drive increased adoption of instruments and consumables. They anticipate that sales volume will offset the revenue impact of lower prices.
- Capital Expenditures: The company anticipates aggregate capital expenditures between $12 million and $17 million for the next 12 months.
- Liquidity: With $393.4 million in cash and marketable securities, management believes current resources are sufficient to meet needs for at least the next 12 months. However, the company expects to continue incurring operating losses in the near term.
- Key Risks:
- Government Funding: A significant portion of revenue comes from academic institutions reliant on government grants (e.g., NIH). Recent pauses in federal funding disbursements and changes to indirect cost rates pose a risk to customer purchasing power.
- Geopolitical & Trade: Trade tensions between the U.S. and China, including tariffs and the designation of competitor Illumina as an "unreliable entity" by China, could impact sales in the Asia-Pacific region (approx. 10% of 2024 revenue).
- Competition & IP Litigation: The company is engaged in significant patent litigation with competitors including NanoString (now Bruker), Vizgen, Parse Biosciences, and Curio Bioscience. While a jury awarded 10x over $31 million in damages against NanoString in 2023, collection remains uncertain due to NanoString's bankruptcy and subsequent acquisition by Bruker.
- Supply Chain: Dependence on single-source suppliers for critical reagents and components creates vulnerability to production delays.
Investor Verification Checklist
- Instrument Sales Volume: Verify the trend in cumulative instrument sales (7,039 total) and the specific quarterly run-rate of new instrument installations to gauge future consumables recurring revenue potential.
- Spatial Portfolio Adoption: Assess the sustainability of the 104% growth in Spatial consumables revenue and whether it can fully offset the decline in the legacy Chromium platform.
- Government Funding Impact: Monitor NIH grant disbursement timelines and budget announcements to evaluate potential headwinds for the academic customer base.
- Litigation Resolution: Track the status of the NanoString/Bruker litigation regarding the collection of the $31 million jury award and the outcomes of pending trials with Vizgen and Parse.
- Price Elasticity: Observe 2025 results to determine if the anticipated price reductions successfully drive the volume increases required to maintain or grow total revenue.